Quince Therapeutics (QNCX) Amortizatization of Intangibles (2018)
Quince Therapeutics (QNCX) posted quarterly Amortizatization of Intangibles of $254000.0 for Q2 2018, down 42.27% quarter-over-quarter from $440000.0 in Q1 2018.
Quince Therapeutics (QNCX) Amortizatization of Intangibles (2018) Analysis & Trends
Quince Therapeutics' Amortizatization of Intangibles history runs 1 years deep, the most recent figure standing at $254000.0 for Q2 2018.
- In Q2 2018, Amortizatization of Intangibles changed N/A year-over-year to $254000.0; the TTM figure through Dec 2018 stood at $694000.0 (changed N/A YoY), while the FY2018 annual figure was $694000.0, changed N/A from the prior year.
- Amortizatization of Intangibles for Q2 2018 stood at $254000.0, down from $440000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $440000.0 in Q1 2018, with the low at $254000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 254,000.00 |
| Jun 30, 2018 | 254,000.00 |
| Mar 31, 2018 | 440,000.00 |
| Mar 31, 2018 | 440,000.00 |